438187

Lovastatin, Sodium Salt

InSolution ≥95%

• Sinônimo(s): InSolution Lovastatin, Sodium Salt
• Fórmula empírica (Notação de Hill): C₂₄H₃₇O₆ · Na
• Peso molecular: 444.54
• Código UNSPSC: 51111800
• NACRES: NA.77

Propriedades

• Nível de qualidade: 100
• Ensaio: ≥95% (HPLC)
• Formulário: liquid
• fabricante/nome comercial: Calbiochem^®
• condição de armazenamento: OK to freeze; avoid repeated freeze/thaw cycles; protect from light
• Condições de expedição: dry ice
• temperatura de armazenamento: −70°C

Descrição

Descrição geral

Carboxylate form of Lovastatin (Cat. No. 438185) that is active in whole cells and cell-free assays. Lovastatin is reported to be an anti-hypercholesterolemic agent that acts as a reversible competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase and blocks a series of biological events including activation of p21^ras by insulin in 3T3-L1 fibroblasts and 3T3-L1 adipocytes, farnesylation of p21^ras, which decreases the pool of intracellular Ras available for subsequent activation by growth factors (including insulin), and N-ras-induced neuronal differentiation. Causes cell cycle arrest in the late G1 phase. Shown to inhibit the stimulation of MAP kinase by insulin in HIRcB cells and block the transcription of the type-I SCR gene in THP-1-derived macrophages. Also blocks PDGF receptor tyrosine phosphorylation and MAP kinase activation by PDGF.

Carboxylate form of Lovastatin (Cat. No. 438185) that is active in whole cells and cell-free assays. Lovastatin is reported to be an anti-hypercholesterolemic agent that acts as a reversible competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase and blocks a series of biological events including activation of p21^ras by insulin in 3T3-L1 fibroblasts and 3T3-L1 adipocytes, farnesylation of p21^ras, which decreases the pool of intracellular Ras available for subsequent activation by growth factors (including insulin), and N-ras-induced neuronal differentiation. Causes cell cycle arrest in the late G1 phase. Shown to inhibit the stimulation of MAP kinase by insulin in HIRcB cells and block the transcription of the type-I SCR gene in THP-1-derived macrophages. Also blocks PDGF receptor tyrosine phosphorylation and MAP kinase activation by PDGF.

Ações bioquímicas/fisiológicas

Cell permeable: yes

Primary Target
HMG-CoA reductase

Reversible: yes

Embalagem

Packaged under inert gas

Advertência

Toxicity: Harmful (C)

forma física

A 10 mM (5 mg/1.13 ml) solution of Lovastatin, Sodium Salt (Cat. No. 438186) in H₂O.

Reconstituição

Following initial thaw, aliquot and freeze (-70°C). Aliquots are stable for up to 6 months at -70°C.

Outras notas

Rao, S., et al. 1999. Proc. Natl. Acad. Sci. USA96, 7197.
Carel, K., et al. 1996. J. Biol. Chem.271, 30625.
McGuire, T.F., et al. 1996. J. Biol. Chem.271, 27402.
Umetani, N., et al. 1996. Biochim. Biophys. Acta1303, 199.
Xu, X.Q., et al. 1996. Arch. Biochem. Biophys.326, 233.
Reusch, J.E.-B., et al. 1995. J. Biol. Chem.270, 2036.

Informações legais

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Informações de segurança

• Código de classe de armazenamento: 12 - Non Combustible Liquids
• Classe de risco de água (WGK): nwg
• Ponto de fulgor (°F): Not applicable
• Ponto de fulgor (°C): Not applicable